RayVa

Apricus Biosciences Files for Orphan Drug Designation for RayVa(TM)

Drug Intended for the Treatment of Raynaud’s Phenomena, Secondary to Systemic Sclerosis   SAN DIEGO, April 13, 2011 (GLOBE NEWSWIRE) — Apricus Biosciences, Inc. (“Apricus Bio”) (Nasdaq:APRI) announced today its filing with the U.S. Food & Drug Administration (“FDA”) requesting […]